Status and phase
Conditions
Treatments
About
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Part 1, Part 2 and Part 3 Inclusion Criteria:
Part 1 and Part 2 Ocular Inclusion Criteria for Study Eye:
Part 3 Ocular Inclusion Criteria for Study Eye:
Ocular Exclusion Criteria for Study Eye:
Exclusion Criteria for Fellow Eye
Exclusion Criteria for Either Eye
Primary purpose
Allocation
Interventional model
Masking
251 participants in 6 patient groups
Loading...
Central trial contact
BP41670 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal